| Autor: |
Cîrjaliu RE; Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania., Tofolean IT; Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania., Tofolean DE; Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania., Chisoi A; Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology (CEDMOG), 'Ovidius' University of Constanta, 900591 Constanta, Romania., Oancea C; Center for Research and Innovation in Precision Medicine of Respiratory Diseases, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Vastag E; Center for Research and Innovation in Precision Medicine of Respiratory Diseases, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Marc M; Center for Research and Innovation in Precision Medicine of Respiratory Diseases, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Bratosin F; Discipline of Infectious Diseases, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Rosca O; Discipline of Infectious Diseases, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania., Fildan AP; Faculty of Medicine, 'Ovidius' University of Constanta, 900470 Constanta, Romania. |
| Abstrakt: |
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates advanced prognostic tools to anticipate disease progression and optimize patient outcomes. This study evaluates the predictive value and diagnostic potential of interleukins interleukin (IL) IL-10, IL-17A, IL1-β, IL-6, chemokine ligand (CXCL), and Monocyte Chemotactic Protein (MCP) for severe coronavirus disease 2019 (COVID-19) and COVID-19 mortality, aiming to correlate cytokine levels with disease severity. Conducted from January 2023 to January 2024, this prospective cohort study involved patients hospitalized with moderate and severe COVID-19 from Romania. This study analyzed statistically significant predictors of severe COVID-19 outcomes. IL-6 and MCP emerged as significant, with hazard ratios (HRs) of 2.35 (95% confidence interval (CI): 1.54-3.59, p = 0.014) and 2.05 (95% CI: 1.22-3.45, p = 0.007), respectively. Compound scores integrating multiple inflammatory markers also demonstrated predictive value; Compound Score 2 had an HR of 2.23 (95% CI: 1.35-3.68, p = 0.002), surpassing most single markers in association with severe disease. Notably, interleukins IL-10 and IL-1β did not show significant associations with disease severity. This study underscores the importance of IL-6 and MCP as robust predictors of severe COVID-19, substantiating their role in clinical assessments to foresee patient deterioration. The utility of compound scores in enhancing predictive accuracy suggests a composite approach may be more effective in clinical settings. |
